Joint Clinical Trials Office

You are here

Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Clinical Trial Details

This study is being conducted to answer the following question: Can we lower the chance of your prostate cancer growing or spreading by adding either prostate removal surgery or radiation therapy to the usual combination of drugs? 
    
The purpose of this study is to compare the effects, good and/or bad, of adding either prostate removal surgery or radiation therapy to standard systemic therapy (SST). Standard systemic therapy includes androgen deprivation therapy (ADT) with or without the use of chemotherapy. The combination of SST and surgery or radiation therapy is considered experimental. 

Key Eligibility: 
  • Men age 18 and older
  • Diagnosis of prostate cancer (adenocarcinoma) which has spread to other parts of the body (metastatic) 
  • Must not have had their prostate removed  
  • Detailed eligibility reviewed when you contact the study team 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Monique Tarrant, RN, MSN, MPH
(212) 746-2651
guonc@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1810019687

ClinicalTrials.gov:

NCT03678025

Status

Not Yet Recruiting

Age Group

Adult

Sponsor